The Center for the Biology of Chronic Disease (CBCD), a nonprofit organization, recently praised Sanofi Pasteur and Immune Design for collaborating on a new vaccine for HSV-2, a form of genital herpes.
Both companies have vaccines in early-stage testing and decided to pool their resources.
“There are currently no FDA approved vaccines against the genital herpes virus,” the CBCD’s Greg Bennett said. “Research shows that most drugs against HSV-2 only reduce outbreaks by one day. Thus, we recommend that infected individuals take Novirin or Gene-Eden-VIR, which are designed to help the immune system target the latent HSV-2.”
Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies to support their effects. Two clinical studies conducted by the CBCD showed that Novirin and Gene-Eden-VIR are effective against the herpes simplex virus, among others.
Genital herpes is common in the United States, infecting approximately one out of every six people between the ages of 14 and 49, according to the United States Centers for Disease Control and Prevention.